Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)
Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)
Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies
Dana-Farber Researchers Presented More Than 50 Research Studies at American Association for Cancer Research Annual Meeting 2026
The Next Wave of Immune Cell Therapy
Dana-Farber Chair of Pathology, Dr. Kathleen Burns, Elected as Fellow of the American Association for the Advancement of Science
Dana-Farber Team Develops Open-Access Predictive Tool to Improve Monitoring of Smoldering Multiple Myeloma
Dana Farber/Boston Children’s Researchers Uncover Distinct Tumor “neighborhoods” with Each Cell Subtype Playing a Specific Role, in Aggressive Childhood Brain Cancer
When Small Cell Lung Cancer Hides from Immune Cells, Blood Vessels May Hold the Key
The Gene Fixer
Dana-Farber Researchers Join Global Cancer Grand Challenges Team Taking on the Dark Proteome
Dana-Farber Research Uncovers Approach to Activating the Immune System Against Metastatic Breast Cancer
Fox Chase Cancer Center Celebrates Innovation, Sustained Growth, and Upward Momentum
Researcher Gains Insight into Rare Genetic Diseases
The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer
Showing 1 - 15 of 1027 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...69 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
